Business Description
Xbrane Biopharma AB
ISIN : SE0007789409
Compare
Compare
Traded in other countries / regions
XBRANE.Sweden7XB.GermanyXBRANs.UK IPO Date
2020-07-21Description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.59 | |||||
| Debt-to-EBITDA | -0.7 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.25 | |||||
| Beneish M-Score | -0.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 177.8 | |||||
| 3-Year EBITDA Growth Rate | 3.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.5 | |||||
| 3-Year FCF Growth Rate | -3.3 | |||||
| 3-Year Book Growth Rate | -20.9 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.9 | |||||
| 9-Day RSI | 43.83 | |||||
| 14-Day RSI | 45.67 | |||||
| 6-1 Month Momentum % | -79.24 | |||||
| 12-1 Month Momentum % | -97.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.43 | |||||
| Cash Ratio | 0.73 | |||||
| Days Inventory | 260.54 | |||||
| Days Sales Outstanding | 2.2 | |||||
| Days Payable | 86.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -162.61 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 15.42 | |||||
| Operating Margin % | -176.82 | |||||
| Net Margin % | -223.59 | |||||
| FCF Margin % | -242.78 | |||||
| ROE % | -128.35 | |||||
| ROA % | -52.19 | |||||
| ROIC % | -57.01 | |||||
| ROC (Joel Greenblatt) % | -400.05 | |||||
| ROCE % | -70.84 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.36 | |||||
| PB Ratio | 1.02 | |||||
| Price-to-Tangible-Book | 1.94 | |||||
| EV-to-EBIT | -1.1 | |||||
| EV-to-Forward-EBIT | -1.38 | |||||
| EV-to-EBITDA | -1.1 | |||||
| EV-to-Forward-EBITDA | -1.38 | |||||
| EV-to-Revenue | 1.9 | |||||
| EV-to-Forward-Revenue | 1.15 | |||||
| EV-to-FCF | -0.78 | |||||
| Price-to-Net-Current-Asset-Value | 1.94 | |||||
| Earnings Yield (Greenblatt) % | -90.91 | |||||
| FCF Yield % | -115.51 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers